

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/009342

International filing date: 21 March 2005 (21.03.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/556,736
Filing date: 25 March 2004 (25.03.2004)

Date of receipt at the International Bureau: 06 May 2005 (06.05.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1314385

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

April 27, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/556,736

FILING DATE: *March 25, 2004*

RELATED PCT APPLICATION NUMBER: *PCT/US05/09342*



Certified by

Under Secretary of Commerce
for Intellectual Property
and Director of the United States
Patent and Trademark Office

032504

11324 U.S. PTO

PTO/SB/16 (05-03)

Approved for use through 4/30/2003. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. EV405281003US

19587 U.S. PTO
60/556736

INVENTOR(S)					
Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)			
ALEXEI M. JAMES ROBERT	VOLOSHIN SWARTZ	Stanford, CA Stanford, CA			
<input type="checkbox"/> Additional inventors are being named on the <u>separately numbered sheets attached hereto</u>					
TITLE OF THE INVENTION (280 characters max)					
PROTEIN EXPRESSION YIELD ENHANCEMENT IN CELL-FREE PROTEIN SYNTHESIS SYSTEMS BY ADDITION OF ANTIFOAM AGENTS					
Direct all correspondence to:		CORRESPONDENCE ADDRESS			
<input checked="" type="checkbox"/> Customer Number <u>24353</u>		<div>Place Customer Number Bar Code Label here</div>			
OR		Type Customer Number here			
<input type="checkbox"/> Firm or Individual Name		Bozicevic, Field & Francis LLP			
Address		200 Middlefield Road, Suite 200			
Address					
City	Menlo Park	State	California	Zip	94025
Country	U.S.A.	Telephone	(650) 327-3400	Fax	(650) 327-3231
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification Number of Pages <u>16</u>		<input type="checkbox"/> CD(s), Number <u> </u>			
<input checked="" type="checkbox"/> Drawing(s) Number of Sheets <u>4</u>		<input checked="" type="checkbox"/> Other (specify) <u>POSTCARD</u>			
<input checked="" type="checkbox"/> Application Data Sheet. See 37 CFR 1.76					
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT					
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.					FILING FEE AMOUNT \$ <u>80.00</u>
<input type="checkbox"/> A check or money order is enclosed to cover the filing fees					
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: <u>50-0815</u>					
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input checked="" type="checkbox"/> No					
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: <u> </u>					

Respectfully submitted,

Date 03/25/2004

SIGNATURE

Pamela J. Sherwood

REGISTRATION NO. 36,677
(if appropriate)

TYPED or PRINTED NAME Pamela J. Sherwood

Docket Number: STAN-353PRV

TELEPHONE (650) 327-3400

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Provisional Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PROTEIN EXPRESSION YIELD ENHANCEMENT IN CELL-FREE PROTEIN SYNTHESIS SYSTEMS BY ADDITION OF ANTIFOAM AGENTS

BACKGROUND OF THE INVENTION

- [01] Protein synthesis is a fundamental biological process, which underlies the development of polypeptide therapeutics, diagnostics, and catalysts. With the advent of recombinant DNA (rDNA) technology, it has become possible to harness the catalytic machinery of the cell to produce a desired protein. This can be achieved within the cellular environment or *in vitro* using extracts derived from cells.
- [02] Over the past decade, the productivity of cell-free systems has improved two orders of magnitude, from about 5 µg/ml-hr to about 500µg/ml-hr. This accomplishment has made *in vitro* protein synthesis a practical technique for laboratory-scale research and provides a platform technology for high-throughput protein expression. It also begins to suggest the feasibility of using cell-free technologies as an alternative means to the *in vivo* large-scale production of protein pharmaceuticals.
- [03] Cell-free protein synthesis offers several advantages over conventional, *in vivo*, protein expression methods. Cell-free systems can direct most, if not all, of the metabolic resources of the cell towards the exclusive production of one protein. Moreover, the lack of a cell wall *in vitro* is advantageous since it allows for better control of the synthesis environment. For example, tRNA levels can be changed to reflect the codon usage of genes being expressed. Also, the redox potential, pH, or ionic strength can be altered with greater flexibility than *in vivo* since cell growth or viability is not a concern. Furthermore, direct recovery of purified, properly folded protein products can be easily achieved.
- [04] *In vitro* translation is also recognized for its ability to incorporate unnatural and isotope-labeled amino acids as well as its capability to produce proteins that are unstable, insoluble, or cytotoxic *in vivo*. In addition, cell-free protein synthesis may play a role in revolutionizing protein engineering and proteomic screening technologies. The cell-free method bypasses the laborious processes required for cloning and transforming cells for the expression of new gene products *in vivo*, and is becoming a platform technology for this field.
- [05] Despite all of the promising features of cell-free protein synthesis, its practical use and large-scale implementation has been limited by several obstacles. Paramount among these are short reaction times and low protein production rates, which lead to poor yields of protein synthesis and excessive reagent cost. The pioneering work of Spirin *et al.* (1988) Science 242:1162-1164 initially circumvented the short reaction times problem with the

development of a continuous flow system. Many laboratories have duplicated and improved upon this work, but they have all primarily used methods that constantly supply substrates to the reaction chamber. This approach increases the duration of the translation reaction and protein yield as compared to the batch system. However, it is inefficient in its use of expensive reagents, generally produces a dilute product, and has not provided significant improvements in production rates.

- [06] The conventional batch system offers several advantages over these continuous and semi-continuous schemes, which include ease of scale-up, reproducibility, increased protein production rates, convenience, applicability for multi-plexed formats for high throughput expression, and more efficient substrate use. These advantages make improving the batch system productivity crucial for the industrial utilization of cell-free protein synthesis. However, using current methodology, when reactions are scaled up there is a loss of efficiency. The decrease in specific protein product yield is especially severe in the systems that require oxygen for oxidative phosphorylation. Increasing the product yield in larger reactions is an essential component of filling this need.

Relevant literature

- [07] US Patent 6,337,191 B1, Swartz *et al.* Kim and Swartz (2000) Biotechnol Prog. 16:385-390; Kim and Swartz (2000) Biotechnol Lett. 22:1537-1542; Kim and Choi (2000) J Biotechnol. 84:27-32; Kim *et al.* (1996) Eur J Biochem. 239: 881-886; Tao and Levy (1993) Nature 362:755-758; Hakim *et al.* (1996) J Immun. 157:5503-5511; Pratt (1984) Coupled transcription-translation in prokaryotic cell-free systems. In: Hames BD, Higgins SJ. Ed. In transcription and translation: a practical approach. New York: IRL press: 179-209.; Davanloo *et al.* (1984) PNAS 81:2035-2039; Cock *et al.* (1999) Biochemistry 259: 96-103; Gill and Hippel (1989) Anal. Biochem. 182:319-326; Kim *et al.* (1999) Europ. J. Biochem. 239: 881-886; Davanloo *et al.* (1984) PNAS 81:2035-2039

SUMMARY OF THE INVENTION

- [08] Compositions and methods are provided for the *in vitro* synthesis of biological molecules in reaction mixtures comprising anti-foam agents. Addition of antifoam agents to cell-free synthesis reactions enhances specific yield of protein in cell-free systems. In one embodiment of the invention, the reaction mix comprising antifoam agent is a scaled up

reaction, e.g. in reaction volumes greater than at least about 15 μ l. Reactions may be performed in various reactors, as known in the art, which include bubble-column reactors.

BRIEF DESCRIPTION OF THE DRAWINGS

- [09] Figure 1 is a graph depicting the protein yield in reactions comprising different antifoam agents.
- [10] Figure 2 is a schematic of a bubble reactor.
- [11] Figure 3 is a graph depicting yields of the protein GMCSF-scFv in a bubble column with total reaction volumes of 1500 μ l, compared to a 15 μ l reaction.
- [12] Figure 4 is graph depicting yields in a bubble column with a reaction volume of 2000 μ l, compared to the 200 μ l thin film reaction, and a 15 μ l Eppendorf tube reaction. With addition of antifoam, the specific yield in each system is comparable.

DETAILED DESCRIPTION OF THE EMBODIMENTS

- [13] Compositions and methods are provided for the *in vitro* synthesis of biological molecules in reaction mixtures comprising antifoam agents to enhance the total, soluble, and active yield of proteins synthesized in cell-free systems. The addition of antifoam can increase yield in small scale reactions, but finds particular benefit in larger scale reactions, particularly reactors providing for aerobic conditions.
- [14] *In vitro* synthesis, as used herein, refers to the cell-free synthesis of biological macromolecules in a reaction mix comprising biological extracts and/or defined reagents. The reaction mix will comprise a template for production of the macromolecule, e.g. DNA, mRNA, etc.; monomers for the macromolecule to be synthesized, e.g. amino acids, nucleotides, etc., and such co-factors, enzymes and other reagents that are necessary for the synthesis, e.g. ribosomes, tRNA, polymerases, transcriptional factors, etc. Such synthetic reaction systems are well-known in the art, and have been described in the literature. A number of reaction chemistries for polypeptide synthesis can be used in the methods of the invention. For example, reaction chemistries are described in U.S. Patent no. 6,337,191, issued January 8, 2002, and U.S. Patent no. 6,168,931, issued January 2, 2001, herein incorporated by reference.
- [15] In one embodiment of the invention, the reaction chemistry is as described in co-pending patent application US 10/643,683, herein incorporated by reference. Oxidative phosphorylation is activated, providing for increased yields and enhanced utilization of

energy sources. Improved yield is obtained by a combination of factors, including the use of biological extracts derived from bacteria grown on a glucose containing medium; an absence of polyethylene glycol; and optimized magnesium concentration. This provides for a homeostatic system, in which synthesis can occur even in the absence of secondary energy sources.

- [16] It is well-known in the art that performance of bioreactors can change dramatically with scale. There are difficulties in maintaining homogeneity in large systems, changes in surface to volume ratios, and changes in the reactions themselves due to increased time frames. In addition to these problems, *in vitro* protein synthesis reactions that activate oxidative phosphorylation may require increased oxygen for optimal performance, the delivery of which becomes more difficult as reaction volume increases.
- [17] Among the more common types of reactors are included, without limitation, stirred tank reactors; bubble column reactors and air-lift reactors, which rely on gas sparging for agitation; etc. The bubble column reactor may be preferred for Cytomim reaction conditions.
- [18] A problem often encountered in commercial fermentation is foaming, which is undesirable, for various reasons, including providing a pathway for contaminating cells to enter the fermenter. Foam in cell cultures has been controlled with the addition of surface-acting chemical agents, although such anti-foam agents usually lower K_La values, reducing the reactor's capacity to supply oxygen and other gases, and may also inhibit cell growth. For *in vitro* synthesis, the hydrophobic components of antifoam would be expected to interfere with protein synthesis and folding, since the catalysts and nascent products are not protected within a cell as they are when proteins are expressed *in vivo*, e.g. by conventional recombinant expression methods. The results provided herein are therefore unexpected.

ANTIFOAM AGENTS

- [19] The *in vitro* protein synthesis reactions of the present invention comprise an antifoam agent. The agent is usually present at a concentration of at least about 0.00007%, and may be at least about 0.0001%, and not more than about 0.001%, usually not more than about 0.007% by weight. Different control strategies, including fixed aliquot, on-demand control, and proportional, integral, and/or derivative control or a combination of them, can be employed to adjust the antifoam agent flow rate in continuous feed reactions. Optimum amounts of antifoam agent additions depend upon variables such as reaction conditions,

antifoam agent type, and the like. Optimum amounts of antifoam agent addition; and where applicable the time span between additions, may be determined empirically during trial runs.

[20] Antifoam agent, as used herein, is a surface acting chemical added to the reaction mixture to facilitate bubble breakage and gas release and to counteract the foaming that can be caused by mixing, sparging, or stirring. Antifoam agents may prevent; eliminate; and/or reduce foam. Antifoam agents may additionally impart positive ancillary surface properties, such as wetting, dispersion, emulsification, solubilization, flow and leveling, adhesion, and gloss.

[21] Many chemical compounds can be used as antifoam agents, these include but are not limited to alkyl polyoxyalkylene glycol ethers; esters; alcohols; siloxanes; silicones; sulfites; sulfonates; fatty acids and their derivatives; etc. A variety of such agents are known and commercially available, e.g. through Sigma Chemicals; J.T. Baker; etc. In some embodiments of the invention, the antifoam agent is other than a detergent.

[22] Among antifoam agents of interest are block copolymers, which provide defoaming/antifoaming action by forming an insoluble monolayer at the air/water interface of the foam. The defoaming activity of a block copolymer is a function of both the cloud point of the copolymer and the use temperature. To select an effective defoamer, a block copolymer is selected whose cloud point is lower than the intended use temperature. Block copolymers with low ethylene oxide content are the most effective defoamers. The PLURONIC® surfactants are widely used as defoamers. The reverse-structure PLURONIC® R surfactants are also effective in defoaming applications. Other antifoam agents of interest include siloxane polymers; mixtures of organic non-silicone polypropylene based polyether dispersions; organic, fatty acid ester-type antifoams; and the like.

REACTION CHEMISTRY

[23] The template for cell-free protein synthesis can be either mRNA or DNA. Translation of stabilized mRNA or combined transcription and translation converts stored information into protein. The combined system, generally utilized in *E. coli* systems, continuously generates mRNA from a DNA template with a recognizable promoter. Either endogenous RNA polymerase is used, or an exogenous phage RNA polymerase, typically T7 or SP6, is added directly to the reaction mixture. Alternatively, mRNA can be continually amplified by inserting the message into a template for QB replicase, an RNA dependent RNA polymerase. Purified mRNA is generally stabilized by chemical modification before it is added to the reaction

mixture. Nucleases can be removed from extracts to help stabilize mRNA levels. The template can encode for any particular gene of interest.

- [24] Other salts, particularly those that are biologically relevant, such as manganese, may also be added. Potassium is generally added between 50-250 mM and ammonium between 0-100mM. The pH of the reaction is generally run between pH 6-9. The temperature of the reaction is generally between 20°C and 40°C. These ranges may be extended.
- [25] Metabolic inhibitors to undesirable enzymatic activity may be added to the reaction mixture. Alternatively, enzymes or factors that are responsible for undesirable activity may be removed directly from the extract. Thirdly, the gene encoding the undesirable enzyme may be inactivated or deleted from the chromosome.
- [26] Vesicles, either purified from the host organism or synthetic, may also be added to the system. These may be used to enhance protein synthesis and folding. This cytomim technology has been shown to activate processes that utilize membrane vesicles containing respiratory chain components for the activation of oxidative phosphorylation. The present methods may be used for cell-free expression to activate other sets of membrane proteins.
- [27] Synthetic systems of interest include the replication of DNA, which may include amplification of the DNA, the transcription of RNA from DNA or RNA templates, the translation of RNA into polypeptides, and the synthesis of complex carbohydrates from simple sugars.
- [28] The reactions may be large scale, small scale, or may be multiplexed to perform a plurality of simultaneous syntheses. Additional reagents may be introduced to prolong the period of time for active synthesis. Synthesized product is usually accumulated in the reactor, and then is isolated and purified according to the usual methods for protein purification after completion of the system operation.
- [29] Of particular interest is the translation of mRNA to produce proteins, which translation may be coupled to *in vitro* synthesis of mRNA from a DNA template. Such a cell-free system will contain all factors required for the translation of mRNA, for example ribosomes, amino acids, tRNAs, aminoacyl synthetases, elongation factors and initiation factors. Cell-free systems known in the art include *E. coli* extracts, etc., which can be treated with a suitable nuclease to eliminate active endogenous mRNA.
- [30] In addition to the above components such as cell-free extract, genetic template, and amino acids, materials specifically required for protein synthesis may be added to the reaction. These materials include salts, polymeric compounds, cyclic AMP, inhibitors for

protein or nucleic acid degrading enzymes, inhibitors or regulators of protein synthesis, oxidation/reduction adjusters, non-denaturing surfactants, buffer components, spermine, spermidine, etc.

[31] The salts preferably include potassium, magnesium, ammonium and manganese salts of acetic acid or sulfuric acid, and some of these may have amino acids as a counter anion. The polymeric compounds may be polyethylene glycol, dextran, diethyl aminoethyl dextran, quaternary aminoethyl and aminoethyl dextran, etc. The oxidation/reduction adjuster may be dithiothreitol, ascorbic acid, glutathione and/or their oxides. Also, a non-denaturing surfactant such as Triton X-100 may be used at a concentration of 0-0.5 M. Spermine and spermidine may be used for improving protein synthetic ability, and cAMP may be used as a gene expression regulator.

[32] When changing the concentration of a particular component of the reaction medium, that of another component may be changed accordingly. For example, the concentrations of several components such as nucleotides and energy source compounds may be simultaneously controlled in accordance with the change in those of other components. Also, the concentration levels of components in the reactor may be varied over time.

[33] Preferably, the reaction is maintained in the range of pH 5-10 and a temperature of 20°-50° C., and more preferably, in the range of pH 6-9 and a temperature of 25°-40° C.

[34] The amount of protein produced in a translation reaction can be measured in various fashions. One method relies on the availability of an assay that measures the activity of the particular protein being translated. Examples of assays for measuring protein activity are a luciferase assay system, and a chloramphenicol acetyl transferase assay system. These assays measure the amount of functionally active protein produced from the translation reaction. Activity assays will not measure full length protein that is inactive due to improper protein folding or lack of other post translational modifications necessary for protein activity.

[35] Another method of measuring the amount of protein produced in a combined *in vitro* transcription and translation reactions is to perform the reactions using a known quantity of radiolabeled amino acid such as ³⁵S-methionine or ¹⁴C-leucine and subsequently measuring the amount of radiolabeled amino acid incorporated into the newly translated protein. Incorporation assays will measure the amount of radiolabeled amino acids in all proteins produced in an *in vitro* translation reaction including truncated protein products. The radiolabeled protein may be further separated on a protein gel, and by autoradiography

confirmed that the product is the proper size and that secondary protein products have not been produced.

REACTION VOLUMES AND GEOMETRIES

[36] While the reactions may be of any volume, the methods are particularly advantageous in a scaled up reaction, where the reaction volume is at least about 15 μ l, usually at least about 50 μ l, more usually at least about 100 μ l, and may be 500 μ l, 1000 μ l, 5000 μ l or greater. In many cases, individual reactions will not be more than about 10 ml, although multiple reactions can be run in parallel. However, it is also anticipated that the present invention will enable scale-up to much larger volumes, as used in commercial bioreactors, which may be configured for volumes of 1 liter, 10 liters, 100 liters, 1000 liters, or more. While the reaction mixture may comprise lipids, e.g. inverted vesicles, it is usually not bounded at the surface by lipid bilayers.

[37] As used herein, the term "small scale" refers to reactions having a volume of about, or less than about, 15 μ l. The methods of the present invention allow "scaled up" reactions, as described above, to maintain substantially consistent yields as compared to a small scale reaction. Yield may be calculated by any convenient method, as long as it is consistently applied between the reactions, e.g. total protein synthesis/ml reaction mixture; soluble protein synthesis/ml reaction mixture; biologically active protein synthesis/ml reaction mixture; and the like. The yield in a scaled up reaction, as compared to a comparable small scale reaction (*i.e.* a reaction comprises the same reactants, differing only in volume), is usually at least about 90%, more usually at least about 95%; and may be at least about 99%. In some cases it has been observed that the yield is actually increased in a scaled up reaction mixture of the present invention.

[38] The system can be run under aerobic and anaerobic conditions, preferably aerobic. To prevent dessication of the reaction, the headspace may be humidified, usually at least about 80% saturated at the working temperature, more usually at least about 90% saturated at the working temperature. Under laboratory conditions it is usually sufficient to seal the chamber enclosing the headspace. The headspace of the reaction chamber may be filled with oxygen or oxygen may be infused into the reaction mixture. Oxygen can be supplied continuously or the headspace of the reaction chamber can be refilled during the course of protein expression for longer reaction times. Besides oxygen, other electron acceptors, such

as nitrate may also be supplied for cell extract previously induced for the appropriate respiration pathway.

[39] Aerated reaction conditions may be provided in a bubble column design. In a bubble column, air is bubbled or sparged into the liquid filled container. The gas can be dispersed into bubbles by sparging the gas into the liquid phase, as in a column. The gas, e.g. oxygen or a mixture comprising oxygen, can be dispersed into bubbles through distribution plates covering the full area of the column, and also airlift reactors, in which the air is confined in a channel by means of a loop or draft tube designed to impart a certain type of overall circulatory pattern to the entire tank. A variety of column configurations are known in the art, and may include variations in size, baffles, head-space, etc. For example, see Bubble Column Reactions, 1st ed.; Wolf-Dieter Deckwer (Gesellschaft für Biotechnologische Forschung mbH, Braunschweig, Germany) ISBN: 0471918113; Oldshue (1983) Biotechnol Adv. 1(1):17-30; Poulsen & Iversen (1999) Biotechnol Bioeng. 64(4):452-8; Poulsen & Iversen (1998) Biotechnol Bioeng. 58(6):633-41; *inter alia*; herein incorporated by reference.

[40] It is to be understood that this invention is not limited to the particular methodology, protocols, cell lines, animal species or genera, constructs, and reagents described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention, which will be limited only by the appended claims.

[41] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs. Although any methods, devices and materials similar or equivalent to those described herein can be used in the practice or testing of the invention, the preferred methods, devices and materials are now described.

[42] All publications mentioned herein are incorporated herein by reference for the purpose of describing and disclosing, for example, the cell lines, constructs, and methodologies that are described in the publications that might be used in connection with the presently described invention. The publications discussed above and throughout the text are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior invention.

- [43] The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the subject invention, and are not intended to limit the scope of what is regarded as the invention. Efforts have been made to ensure accuracy with respect to the numbers used (e.g. amounts, temperature, concentrations, etc.) but some experimental errors and deviations should be allowed for. Unless otherwise indicated, parts are parts by weight, molecular weight is average molecular weight, temperature is in degrees centigrade; and pressure is at or near atmospheric.

EXPERIMENTAL

Example 1

- [44] The addition of antifoaming agents to cell-free protein synthesis system was tested. Five different antifoams agents were added to the PANOX (Kim and Swartz 2001 Biotechnol. Bioengineer. 74:309-316) cell-free system and were found to enhance the total, soluble, and active yield of *E. coli* chloramphenicol acetyl transferase (CAT) (Figure 1). Figure 2 shows the basic outline of the bubble reactor. Figures 3 and 4 compare the yield of GMCSF-VL-VH mammalian protein construct and CAT in the bubble reactor at large scale vs. small scale in Eppendorf tubes. The agents are listed in Table 1, and reaction components in Tables 2 and 3.
- [45] For the cytomim system, the components listed in Table 2 are mixed in the indicated concentrations (Jewett and Swartz, co-pending application 10/643,683). For the PANOX system, the components listed in Table 3 are mixed in the indicated concentrations as described by Swartz and Kim, "Regeneration of Adenosine Triphosphate from Glycolytic Intermediates for Cell-Free Protein Synthesis", Biotechnology and Bioengineering, Vol. 74, 4, August 20, 2001.
- [46] For the CAT protein expression, the DNA used as the template in the system is pK7-CAT circular plasmid that includes the T7 promoter followed by the gene encoding the *E. coli* protein Chloramphenicol Acetyl Transferase. The structural gene is followed by a T7 terminator.
- [47] For GMCSF-scFv protein expression, the DNA used as the template in the system is the pK7-GMCSF-VL-VH circular plasmid that includes the T7 promoter followed by the gene encoding the GMCSF protein (Mi-Hua Tao, 1993) and fused to the gene encoding the scFv

fragment of the murine lymphoma antibody, 38C13 (Hakim, 1996) through a 5-amino acid linker (glycine₄ – serine). The structural gene is followed by a T7 terminator.

[48] S30 cell extract was prepared from E. coli K12 (strain A19) according to the procedures of Pratt (1984). No DL-dithiothreitol was added to the cell lysate after homogenization. T7 RNA polymerase was prepared from the culture of E. coli strain BL21 (pAR1219) according to the procedures of Davanloo et al (1984).

[49] For GMCSF-VL-VH expression, the expression system was modified to enhance protein folding and disulfide bond formation using the following additions. Cell free extract is pretreated with 0.85 mM iodoacetamide (IAM) for 30 minutes at room temperature prior to addition to the reaction mixture. E. coli DsbC was added at 50 ug/ml concentration. Oxidized and reduced glutathione are added to the reaction mixture at concentrations of 4mM and 1mM, respectively.

[50] E.coli DsbC was prepared by overexpressing strain BL21(DE3) (pETDsbC) and was purified with a cobalt IMAC column. The selected fractions were dialyzed against S30 buffer (Pratt, 1984) containing 5 mM DTT to reduce the active site of DsbC.

[51] The antifoam agents were purchased from the listed vendors, and added in the the indicated amounts. In some cases the antifoam was diluted in water such as to add 1 µl of antifoam/ water mixture to every 15 µl of cell-free reaction.

[52] For the Eppendorf test tube method, the mixture of appropriate volume is pipetted on the bottom of an Eppendorf test tube. The tube is incubated at 37° C for the appropriate period of time (3 hours for the PANOx, 6 hours for the Cytomim system).

Table 1

Antifoam Name	Manufacturer
Antifoam 204	Sigma
Antifoam B	J.T. Baker
Antifoam O-30	Sigma
Triton X-705	Sigma
Antifoam SE-15	Sigma

Table 2

Reagent make-up and concentrations for the Cytomim cell-free protein synthesis system.

Reagent	Concentration
Magnesium Glutamate	8 mM
Ammonium Glutamate	10 mM
Potassium Glutamate	130 mM
ATP	1.20 mM
GTP	0.86 mM
UTP	0.86 mM
CTP	0.86 mM
Folinic acid	34 ug/ml
tRNA	170.6 ug/ml
20 amino acids	2 mM
Cysteine	9 mM
Pyruvate	30 mM
NAD	3.3 mM
CoA	2.7 mM
Oxalic Acid	4 mM
Spermidine	1.5 mM
Putrescine	1 mM
T7 RNA polymerase	0.10 mg/ml
Plasmid	0.0133 mg/ml
S30 extract *	6/25 total reaction volume

Table 3

Reagent make-up and concentrations for the PANOx cell-free protein synthesis system.

Reagent	Concentration
Magnesium Glutamate	20 mM
Ammonium Glutamate	10 mM
Potassium Glutamate	170 mM
ATP	1.2 mM
GTP	0.86 mM
UTP	0.86 mM
CTP	0.86 mM
Folinic Acid	34 ug/ml
tRNA	170.6 ug/ml
20 Amino Acids	2.0 mM
Phosphoenolpyruvate	30 mM
NAD	0.33 mM
CoA	0.27 mM
Oxalic Acid	2.70 mM
Putrescine	1.00 mM
Spermidine	1.50 mM
T7 RNA Polymerase	0.1 mg/ml
Plasmid Template	0.0133 mg/ml
S30 Extract *	3.6 ul/ 15ul RXN

[53] The bubble column reactor consists of a column with a diameter of 1 cm ID and 5 cm height. Cell-free reaction mixture (Tables 1 and 2) was pipetted inside the column (Figure 2). Gas is bubbled through a small jet (less than 1 mm diameter) at the bottom of column from a compressed gas tank.

[54] For the Cytomim system (as described by Jewett and Swartz, co-pending application 10/643,683), pure oxygen gas was used and the reaction lasted for a maximum of 4 hours at 37°C. For the PANOx reactions, argon gas was used and the reaction time was 3 hours at

37°C. The bubble size was approximately 0.5 cm in diameter and bubbling rate was approximately 1 bubble/ second. Without addition of antifoam, the cell-free protein synthesis reaction immediately foams out of the top of the column reactor. No protein is produced. Upon addition of antifoam (Sigma 204, 1/1000 -1/10000 volume antifoam/ volume reaction), the protein synthesis reaction proceeds with minimal foaming for up to 3.5 to 4 hours producing protein yields comparable to those from 15 µl Eppendorf tube reactions (see Figure 3 and 4).

[55] The amount of synthesized protein was estimated from the measured TCA-precipitated radioactivities in a liquid scintillation counter (LS3801, Beckman Coulter, Inc.). After centrifuging samples at 4 °C and 15,000 RCF for 15 minutes, supernatants were taken and used to determine soluble yield by TCA precipitation and scintillation counting. The procedures in detail were described previously (Kim et al, 1996 b).

[56] Results are shown for CAT as well as for a GM-CSF-scFv fusion protein. The entire reaction is run in batch mode with no post-start additions.

[57] These data demonstrate that, in different scales and with different reaction geometries and proteins, the addition of an antifoam agent provides for improved in vitro protein synthesis. In particular, the antifoam agents provide enhanced yield in a scale up reaction using a bubble-column.

WHAT IS CLAIMED IS:

1. A method for enhanced synthesis of biological macromolecules *in vitro*, the method comprising:
synthesizing said biological macromolecules in a reaction mixture comprising an antifoam agent.
2. The method of Claim 1, wherein said synthesis of biological macromolecules comprises translation of mRNA to produce polypeptides.
3. The method of Claim 2 wherein said synthesis also comprises transcription of mRNA from a DNA template.
4. The method of Claim 2, wherein said reaction mix comprises a volume of greater than about 15 μl .
5. The method of Claim 2, wherein said reaction mix comprises a volume of greater than about 100 μl .
6. The method of Claim 4, wherein said reaction has a yield that is at least about 90% of the yield in a comparable small scale reaction.
7. A reaction mixture for synthesis of biological macromolecules *in vitro*, the improvement comprising:
an antifoam agent.
8. The reaction mixture of Claim 7, wherein said reaction mix comprises a volume of greater than about 15 μl .
9. The reaction mixture of Claim 7, wherein said reaction mix comprises a volume of greater than about 100 μl .
10. The reaction mixture of Claim 7, wherein said reaction generates a yield that is at least about 90% of the yield in a comparable small scale reaction.

ABSTRACT OF THE INVENTION

- [58] Compositions and methods are provided for the *in vitro* synthesis of biological molecules in reaction mixtures comprising anti-foam agents. The reaction mix comprising antifoam agent may be a scaled up reaction, e.g. in reaction volume greater than at least about 15 ul. Reactions may be performed in various reactors, as known in the art, which include stirred reactors, bubble-column reactors; and the like.

Figure 1






Figure 2




Typical bubble reactor is shown from the side. The bubble reactor is capped at the top with a small opening in the cap to avoid gas pressure build-up. Bubbles rise from the jet at the bottom to the surface. The cytomim system requires oxygen and releases CO₂ gas. The PANOx system does not require oxygen, but probably releases CO₂ as foaming occurs without the addition of antifoam. A slow rate of bubbling in the presence of antifoam will remove the CO₂ without foaming.

Figure 3



We compare here yields of a GMCSF-scFv vaccine candidate (GLH) in a bubble column with a total reaction volume of 1500 ul (Reactor 1500) to yields attained in a 15 ul Eppendorf tube reaction (15). With addition of antifoam, total, soluble, and active yields in the bubble column are comparable to those from the small scale reaction.

Figure 4



We compare here yields of CAT in a bubble column with a total reaction volume of 2000 ul (Reactor 2000), to those from a thin film reaction at 200 ul (Thin Film 200), and a 15ul Eppendorf tube reaction (15). With addition of antifoam, the specific protein synthesis yields in the bubble column are comparable to the thin film and small scale reactions.

APPLICATION INFORMATION

Application Type::	Provisional
Title::	PROTEIN EXPRESSION YIELD ENHANCEMENT IN CELL-FREE PROTEIN SYNTHESIS SYSTEMS BY ADDITION OF ANTIFOAM AGENTS STAN-353PRV
Attorney Docket Number::	
Request for Non-Publication?::	
Assignee for Publication::	
Total Drawing Sheets::	4
Small Entity?::	Small
License US Govt. Agency::	No
Contract or Grant Numbers::	
Sequence Submission?::	No
Computer Readable Form (CRF)?::	

INVENTOR INFORMATION

Inventor One Given Name::	ALEXEI M.
Family Name::	VOLOSHIN
Postal Address Line One::	334 Olmsted road
Postal Address Line Two::	Apt. 312
City::	Stanford
State or Province::	CA
Postal or Zip Code::	94305
Citizenship Country::	Russia
Inventor Two Given Name::	JAMES ROBERT
Family Name::	SWARTZ
Postal Address Line One::	Dept Chem Eng, Stauffer III
Postal Address Line Two::	
City::	Room 113
State or Province::	Stanford, California
Postal or Zip Code::	94305-5025
Citizenship Country::	US

CORRESPONDENCE INFORMATION

Correspondence Customer Number::	24353
Telephone One::	(650) 327-3400
Telephone Two::	(650) 833-7790
Fax::	(650) 327-3231
Electronic Mail::	sherwood@bozpat.com

REPRESENTATIVE INFORMATION

Representative Customer Number:: 24353

CONTINUITY INFORMATION

This application is a:: Provisional
> Application One::
Filing Date::

PRIOR FOREIGN APPLICATIONS

Foreign Application One::
Filing Date::
Country::
Priority Claimed::

From the INTERNATIONAL BUREAU

PCT**NOTIFICATION CONCERNING
SUBMISSION OR TRANSMITTAL
OF PRIORITY DOCUMENT**

(PCT Administrative Instructions, Section 411)

To:

SHERWOOD, Pamela, J.
BOZICEVIC, FIELD & FRANCIS LLP
1900 University Avenue, Suite 200
East Palo Alto, CA 94303
ETATS-UNIS D'AMERIQUE

Date of mailing (day/month/year) 01 June 2005 (01.06.2005)	
Applicant's or agent's file reference STAN-353WO	IMPORTANT NOTIFICATION
International application No. PCT/US05/009342	International filing date (day/month/year) 21 March 2005 (21.03.2005)
International publication date (day/month/year)	Priority date (day/month/year) 25 March 2004 (25.03.2004)
Applicant THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY et al	

1. By means of this Form, which replaces any previously issued notification concerning submission or transmittal of priority documents, the applicant is hereby notified of the date of receipt by the International Bureau of the priority document(s) relating to all earlier application(s) whose priority is claimed. Unless otherwise indicated by the letters "NR", in the right-hand column or by an asterisk appearing next to a date of receipt, the priority document concerned was submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b).

2. (If applicable) The letters "NR" appearing in the right-hand column denote a priority document which, on the date of mailing of this Form, had not yet been received by the International Bureau under Rule 17.1(a) or (b). Where, under Rule 17.1(a), the priority document must be submitted by the applicant to the receiving Office or the International Bureau, but the applicant fails to submit the priority document within the applicable time limit under that Rule, the attention of the applicant is directed to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.

3. (If applicable) An asterisk (*) appearing next to a date of receipt, in the right-hand column, denotes a priority document submitted or transmitted to the International Bureau but not in compliance with Rule 17.1(a) or (b) (the priority document was received after the time limit prescribed in Rule 17.1(a) or the request to prepare and transmit the priority document was submitted to the receiving Office after the applicable time limit under Rule 17.1(b)). Even though the priority document was not furnished in compliance with Rule 17.1(a) or (b), the International Bureau will nevertheless transmit a copy of the document to the designated Offices, for their consideration. In case such a copy is not accepted by the designated Office as the priority document, Rule 17.1(c) provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.

<u>Priority date</u>	<u>Priority application No.</u>	<u>Country or regional Office or PCT receiving Office</u>	<u>Date of receipt of priority document</u>
25 March 2004 (25.03.2004)	60/556,736	US	06 May 2005 (06.05.2005)

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No. +41 22 740 14 35

Authorized officer

Smahi Abderrezak

Facsimile No. +41 22 338 89 65
Telephone No. +41 22 338 8021